Past exam of the biochemistry and Molecular Biology course of the University of Cambridge / 2025 / Paper 2

For a primary sigma factor of the ${\sigma }^{70}$ family, distinguish the following regions. Region 1.1 restrains inappropriate DNA binding by free sigma factor and must move out of the downstream-DNA channel during formation of the open RNA polymerase complex; region 1.2 contributes to recognition around the discriminator downstream of the $-10$ element. Domain 2 binds the RNA polymerase core, recognizes the $-10$ gene promoter element and helps melt the duplex and stabilize the exposed non-template strand. Domain 3 recognizes an extended $-10$ element; its region 3.2 projects toward the active-centre channel, helps position template and initiating substrates, and must be displaced as the nascent RNA grows. Domain 4 recognizes the $-35$ element through a helix-turn-helix motif and contacts the RNA polymerase beta flap and some transcription activators. Domains 2 and 4 supply the principal $-10$ and $-35$ sequence recognition, with the other regions controlling opening and productive initiation. This domain map concerns the ${\sigma }^{70}$ family, rather than every structurally distinct bacterial sigma factor.^[ref]

Incubate a labelled precursor messenger RNA containing an authentic $3^{\prime }$-processing signal with a HeLa nuclear extract, then resolve the products by denaturing polyacrylamide gel electrophoresis. With ATP, the upstream cleavage product acquires a heterogeneous poly(A) tail. Replace ATP with an appropriate non-incorporable analogue, such as alpha,beta-methylene-ATP: a discrete product ending at the normal cleavage site still appears, but the extended tail does not. Thus cleavage can occur when polyadenylation is blocked; it is not cleavage brought about by synthesis of the tail.^[ref]

Conversely, supply an RNA substrate already ending at the normal cleavage site: addition of ATP and the appropriate poly(A) polymerase machinery can extend its free $3^{\prime }$ hydroxyl without any new endonucleolytic cut.^[ref] Compare precursor, pre-cleaved substrate, no-extract and no-ATP controls, and map the product ends to distinguish correct processing from non-specific degradation. These are separable reactions, normally coordinated in one processing complex. Their separability does not imply that they use completely independent recognition factors.

A detectable burst kinetics phase requires rapid formation and detection of an initial reaction product, followed by a slower step that regenerates competent enzyme. A common hydrolysis mechanism iswhere $E^{\ast }$ can be a covalent acyl-enzyme intermediate. With excess substrate, rapid binding and $k_2\gg k_3$, the first turnover rapidly releases $P_1$ and traps much of the enzyme as $E^{\ast }$. Subsequent turnovers wait for the slow regeneration step. The measured product must report the fast step: monitoring only $P_2$ need not reveal a burst. Fast mixing and sufficient time resolution are needed, while spontaneous substrate hydrolysis, depletion and enzyme inactivation must be excluded.

For an illustrative saturated two-step cycle, initially unmodified enzyme concentration $E_T$ givesThe second term approaches a burst amplitude near $E_T$ when $k_2\gg k_3$, followed by the slower steady-state slope. A covalent intermediate is a useful example, not a logical requirement for every possible burst mechanism.

The enzyme adenylate kinase rapidly interconverts the adenine nucleotides:For approximately fixed conditions and near-equilibrium activity ratios,The AMP:ATP ratio responds quadratically to ADP:ATP. Doubling ADP:ATP therefore quadruples AMP:ATP. In working skeletal muscle, ATP is also buffered by creatine kinase and continuing ATP production, so its fractional change is relatively small. The initially smaller AMP pool can undergo a much larger fractional increase, providing a sensitive signal of energetic stress to regulators such as AMP-activated protein kinase. This concerns sensitivity of relative changes; it does not mean that the absolute AMP concentration exceeds ATP.

The mitochondrial fission-fusion cycle is continuous remodeling of a mitochondrial population by division and merger. In mammalian biological cells, mitofusins promote fusion of outer mitochondrial membranes, while OPA1 supports fusion of inner mitochondrial membranes. Fusion mixes matrix contents and permits functional complementation between mitochondria. Genetic disruption and rescue of mitofusins demonstrated their requirement for normal mitochondrial fusion.^[ref]

For fission, recruited Drp1 assembles at constrictions and uses GTP-dependent remodeling to help divide the organelle.^[ref] The balance controls network shape, distribution and quality control. Division can help distribute mitochondria to daughter biological cells and segregate damaged portions for mitophagy; fusion can restore mixed contents. These are regulated competing events in a network, not an obligatory synchronized sequence that every mitochondrion completes on a fixed timetable.

A steroid hormone crosses the lipid bilayer and binds an intracellular nuclear receptor. For a cytoplasmic glucocorticoid receptor, ligand binding alters association with molecular chaperones, exposes nuclear-targeting functions and promotes accumulation in the cell nucleus. Other steroid hormone receptors already have substantial nuclear localization. The activated receptor binds specific hormone response elements in DNA, often as a dimer, and changes recruitment of transcription coactivators or transcription corepressors. These factors alter local chromatin and recruitment or activity of the RNA polymerase II machinery. The result is selective activation or repression of target genes, followed by altered messenger RNA and protein abundance; the hormone itself does not act as an RNA polymerase or directly rewrite the DNA sequence.

Fucci uses two fluorescent protein fusions carrying cell-cycle-regulated degradation signals: a red/orange Cdt1 fragment accumulates mainly in G1 phase, whereas a green geminin fragment accumulates through S phase, G2 phase and much of M phase. Opposing activities of SCF ubiquitin ligase and anaphase-promoting complex regulate reporter degradation through the ubiquitin-proteasome system; the fluorophores report those regulated stabilities rather than simply measuring total endogenous Cdt1 and geminin.^[ref]

Live imaging follows individual biological cells through red, overlap and green states, allowing measurements of phase timing, spatial patterns and responses to perturbation without repeatedly fixing the sample. Flow cytometry can separate populations by reporter color. The basic two-color version does not independently resolve every phase, and a color transition is an indirect readout of ubiquitin ligase activity. Validate timing with DNA content or a DNA replication marker and control for altered reporter expression, fluorophore maturation and drug effects on degradation.

Two distinct possibilities are a second mutation affecting drug sensitivity of the targeted receptor tyrosine kinase, so that it remains active at the achieved inhibitor concentration, and activation of a bypass signaling route, such as another receptor tyrosine kinase or a downstream Ras or protein kinase component, restoring proliferation despite inhibition of the original target. The resistant population may arise by selection of rare pre-existing biological cells or by later acquisition of a change; recurrence alone cannot distinguish those histories. Compare target engagement, target phosphorylation and downstream signaling in the original and recurrent samples, with DNA sequencing and functional rescue or perturbation of the candidate resistance mechanism.

An antibody-drug conjugate couples an antibody against a tumor-associated surface antigen to a potent cytotoxic payload through a suitable chemical linker. Binding enriches delivery to biological cells displaying the target. Many designs undergo receptor-mediated endocytosis, trafficking through endosomes to a lysosome, and release of an active drug through linker cleavage or degradation of the antibody. The released payload can disrupt microtubules or damage DNA, killing the target biological cell. Specificity comes from targeted delivery combined with controlled payload release. It is relative rather than absolute: normal biological cells may share the antigen, and a membrane-permeable released payload can also affect neighboring biological cells. Successful action therefore depends on antigen abundance, accessibility, internalization, linker stability and payload sensitivity.

The hydrogenosomes and mitosomes are specialized mitochondrion-related organelles found in various anaerobic or oxygen-limited eukaryotes. Typical hydrogenosomes support anaerobic ATP production, converting substrates such as pyruvate into products including acetate, carbon dioxide and molecular hydrogen. Substrate-level phosphorylation supplies ATP, while hydrogenase disposes of reducing equivalents as hydrogen; oxygen is not the terminal acceptor of a conventional respiratory chain in this pathway.^[ref]

The mitosomes retain selected essential metabolic functions but do not generate ATP by oxidative phosphorylation. In Giardia, their role includes iron-sulfur cluster assembly and protein maturation, demonstrated using organelle markers and biochemical reconstitution.^[ref] Their functions are lineage-dependent: Entamoeba histolytica mitosomes compartmentalize a sulfate activation pathway.^[ref] Thus neither organelle class should be described simply as a nonfunctional mitochondrion.

The catalytic serine residue supplies a nucleophile: its side-chain oxygen attacks the carbonyl carbon of the beta-lactam ring. This generates a tetrahedral intermediate, followed by opening of the ring and formation of a covalent acyl-enzyme intermediate. Subsequent attack by activated water hydrolyzes that intermediate and regenerates the enzyme. The serine residue performs covalent catalysis and is regenerated, rather than being consumed as a reagent.

An appropriately positioned general base helps remove the proton from the serine residue hydroxyl, increasing its nucleophilicity. A lysine residue, such as Lys73 in the class A beta-lactamase catalytic network, is a plausible participant; its protonation state depends on its active-site environment and interactions with other residues. A glutamate residue, notably Glu166, also participates in proton transfer and activation of the water needed for deacylation. Efficient catalysis requires proton-transfer chemistry as well as positioning the attacking oxygen. The precise division of roles during acylation depends on the enzyme state, so the drawing alone cannot assign a complete mechanism to one residue.^[ref]

Bond c, the carbonyl-carbon–nitrogen bond within the four-membered beta-lactam ring, is cleaved. Hydrolysis opens the cyclic amide; it does not cut the side-chain amide or a carbon–carbon bond. The resulting open-ring product no longer has the intact beta-lactam pharmacophore required for its usual antibacterial action.

The compound imidazole resembles the metal-coordinating part of the histidine side chain and competes for binding to the nickel sites in immobilized metal affinity chromatography. At the lower concentration in the wash, it helps displace weakly or non-specifically bound proteins while the multiple contacts of the histidine tag retain the desired enzyme. At the higher elution concentration, competition is strong enough to displace the tagged enzyme. Low imidazole improves washing; high imidazole elutes the target. Remove or match the elution-buffer components before interpreting downstream assays, and verify purity independently of total protein concentration.

The dilution in the Bradford assay is $1000/5=200$. Read the fitted line rather than assuming it passes through the origin: the two absorbances correspond approximately to $4.3$ and $15\mu \mathrm{g}\mathrm{m}{\mathrm{L}}^{-1}$ in the assay mixture. ThereforeMultiplying by the $0.500\mathrm{mL}$ eluate volume gives about $0.43\mathrm{mg}$ of TEM-1 and $1.5\mathrm{mg}$ of TEM-52. Only TEM-52 meets the requirement.

Assuming the same recovery per culture volume, the required volumes areUse approximately $120\mathrm{mL}$ or more for TEM-1; the existing $50\mathrm{mL}$ is sufficient for TEM-52. Rounding the former up to $125\mathrm{mL}$ is sensible given graphical precision. Reading the lower standard as $4$–$4.5\mu \mathrm{g}\mathrm{m}{\mathrm{L}}^{-1}$ gives a corresponding requirement of roughly $110$–$125\mathrm{mL}$, not an exact integer volume. These estimates assume comparable dye response to bovine serum albumin, suitable buffer blanks and that recovered protein is the purified target; contaminants would inflate the inferred target yield.

For the Hanes-Woolf plot, the slope is $1/V_{\max }$, the vertical intercept is $K_m/V_{\max }$, and the horizontal intercept is $-K_m$. The lines have approximately equal slopes, $0.50\min \mu {\mathrm{M}}^{-1}$. The dashed TEM-1 line intercepts the vertical axis at about $13\min$, while the dotted TEM-52 line intercepts it at about $2.5\min$. ThusThe negative-axis intercepts independently give approximately $-26$ and $-5\mu \mathrm{M}$. Allow normal graph-reading uncertainty, especially at the smaller intercept. The limiting rates are similar; the Michaelis constant is substantially lower for TEM-52. A Michaelis constant is not generally a binding dissociation constant, and calculating a turnover number additionally requires the concentration of active enzyme.

The displayed separation between the two entrance landmarks increases from approximately $6.2$ to $7.7\text{A˚}$ in TEM-52, indicating a wider opening. The Gly238-to-Ser substitution can alter backbone packing and loop geometry; its effect is not simply the steric size of the new side chain. Increased accessibility or altered productive positioning could increase the effective association rate for penicillin G, producing a lower apparent Michaelis constant without changing the limiting catalytic step. In a simple Michaelis-Menten kinetics scheme, $K_m=(k_{-1}+k_{\mathrm{cat}})/k_1$, so increasing $k_1$ can lower $K_m$.

The structural change is consistent with improved access and the lower measured $K_m$, while similar $V_{\max }$ suggests similar limiting turnover under these conditions. It does not uniquely establish the mechanism or prove tighter equilibrium binding. TEM-52 contains additional substitutions, so a matched single-substitution series would be needed to isolate the contribution of residue 238. Structural work on TEM-52 independently supports the importance of remodeling access to its active site.^[ref]

The bulky substituents of ceftazidime can hinder productive entry into the more restricted TEM-1 active site. A wider entrance in TEM-52 could accommodate this substrate and allow its beta-lactam ring to be hydrolyzed. The prediction is reduced susceptibility of TEM-52-expressing bacteria compared with matched TEM-1-expressing bacteria. This is a mechanistic prediction, not a quantitative conclusion from the penicillin G data: entry alone does not guarantee efficient catalytic chemistry for a different substrate. Test ceftazidime hydrolysis directly and measure its minimum inhibitory concentration in an otherwise matched bacterial background, controlling enzyme expression, growth, drug entry and other resistance mechanisms.

The ADP addition containsDuring the initial stimulated interval, the plotted oxygen concentration falls from about $240$ to $207\mu \mathrm{M}$. The chamber volume after this addition is $1.900+0.050+0.050+0.010=2.010\mathrm{mL}$, givingThe conventional phosphorylation-to-oxidation ratio counts ATP formed per oxygen atom reduced, so its denominator is twice the number of oxygen molecules:This assumes the added ADP is phosphorylated and uses the displayed total oxygen loss over the pulse; it is an apparent experimental ratio. A separate correction for background respiration or proton leak would change the denominator and must be specified explicitly. Dividing by oxygen molecules without the factor of two would instead give an ATP:${\mathrm{O}}_2$ ratio near $3$.

Succinate is the most plausible substrate. Its oxidation by succinate dehydrogenase, or respiratory complex II, supplies electrons to the ubiquinone pool, bypassing respiratory complex I. Electron passage through respiratory complex III and cytochrome c oxidase supports a lower phosphorylation yield than entry through NADH at respiratory complex I, consistent with an apparent phosphorylation-to-oxidation ratio around $1.5$. The later involvement of a mitochondrial dicarboxylate carrier is additional evidence because succinate is one of its transported substrates. The ratio alone is not a chemically unique identification: other electron-entry routes and altered coupling can also produce a similar yield. Confirm by comparing defined substrates and sensitivity to a succinate dehydrogenase inhibitor.

Hexokinase consumes exported ATP in the reactionThe adenine nucleotide translocator imports regenerated ADP, permitting ATP synthase to use the proton-motive force. Increased proton return reduces the opposing gradient and allows faster activity of the electron transport chain and oxygen consumption: this is respiratory control. The first hexokinase additions therefore increase demand and respiration. By about the fourth addition, demand no longer limits the measured flux: the respiratory and transport system has reached its available capacity, so more hexokinase cannot increase it. This does not imply that hexokinase ceases functioning, and its zero incremental control at maximal demand does not make it dispensable for maintaining that demand.

At low ATP demand, the proton-motive force is high and much of the remaining oxygen consumption supports proton leak. Increasing leak conductance then creates a substantial extra demand for proton pumping and strongly changes respiratory flux. At high phosphorylation demand, proton return through ATP synthase is large, the proton-motive force is lower, and leak contributes a much smaller part of total proton return. Control of oxygen consumption shifts toward substrate supply and the respiratory machinery, so the leak flux control coefficient becomes small. The plot's value near zero does not mean that the physical leak current vanishes; the separate maximal-rate table likewise gives a small nonzero coefficient, $0.04$.

The mitochondrial dicarboxylate carrier is an inner-membrane transport protein that exchanges suitable dicarboxylates, including succinate and malate, with counter-substrates such as phosphate. In this experiment, it supplies external succinate to the matrix side of respiratory complex II; the inner mitochondrial membrane does not simply allow unrestricted diffusion of the charged substrate. Without adequate uptake, substrate delivery would restrict respiration even if the respiratory enzymes remained intact. Its essentiality is substrate- and preparation-dependent: it is not the obligatory entry route for every possible respiratory fuel.

The reported coefficients add toFor a complete set of independently scaled activities controlling a steady-state flux, the flux summation theorem gives ${\sum }_i{C}_i^J=1$, where $C_i^J=\partial \ln J/\partial \ln E_i$. One way to see this is to scale all reaction capacities by the same factor: steady-state concentrations can remain the same while all fluxes scale by that factor, so the summed logarithmic sensitivities equal one. The listed processes therefore leave a net coefficient of about $0.14$ unaccounted for under the model assumptions. Measurement uncertainty, imperfect inhibitor specificity or incompatible measurements could also contribute to the discrepancy. Control is distributed; neither the sum nor the largest individual coefficient identifies a single universal rate-limiting step.

Important unlisted candidates include ATP synthase, the mitochondrial phosphate carrier, and succinate dehydrogenase itself, which supplies electrons from succinate to ubiquinone. Availability or transfer of ubiquinone and cytochrome c, and associated transport or metabolite constraints, may also need explicit treatment depending on how the pathway is grouped. ATP synthesis, phosphate supply and substrate oxidation have not all been individually represented. Respiratory complex I is absent from the table but is not required for the direct forward route from succinate into the ubiquinone pool; its omission alone does not account for missing control of that route.

Titrate the omitted activities using small perturbations around the same steady-state condition, measuring oxygen consumption and calculating local slopes rather than assigning control from complete inhibition. For example, suitable ATP synthase, succinate dehydrogenase and carrier perturbations could test their contributions, with independent checks of inhibitor selectivity and activity loss. Measure ATP production alongside oxygen consumption, as well as mitochondrial membrane potential, to separate a change in phosphorylation efficiency from a change in electron flux. Check chamber oxygen availability, mitochondrial integrity, substrate abundance and assay reproducibility.

Repeat the control measurements across ADP demands and with defined alternative substrates. Carefully titrated FCCP can test respiratory capacity when proton-gradient backpressure is relieved, but the uncoupled state is a different operating condition and does not itself reveal the coupled-state coefficients. Fit the measured local sensitivities with uncertainty and test whether the expanded set satisfies the flux summation theorem. This distinguishes omitted control from technical inconsistency and shows whether the distribution changes with demand.

Culture each patient and control sample under matched conditions, including equivalent growth-factor withdrawal where appropriate, then prepare paired unstimulated and PDGF-stimulated samples with the same stimulation time. Rapidly lyse on ice with suitable detergents and protease and phosphatase inhibitors. Measure protein concentration and load equal amounts after SDS-PAGE sample preparation. Separate the proteins with molecular-mass markers, transfer them to a suitable membrane, verify transfer and block non-specific binding. Incubate with the Ras-PST25 primary antibody, wash, add a detectable secondary antibody, wash again and record the signal within its linear range. Preserve the original phosphorylation state and compare equal, verifiably transferred inputs. Include a total-protein loading measure, appropriate antibody controls and independent biological replicates; use matched exposures rather than independently rescaling lanes.

The healthy sample establishes the basal and normal stimulated patterns for the same cell type and handling conditions. Sample A contains bands around $96$ and $30\mathrm{kDa}$ in both conditions; PDGF additionally induces bands near $73$, $62$ and $44$–$45\mathrm{kDa}$. These are compatible, respectively, with stimulated Raf, Akt and unresolved MEK/ERK signals, given the supplied masses. Ligand-dependent appearance of those bands is the normal comparison for suspected constitutive signaling. Their identities remain provisional until confirmed with target-specific reagents. The unchanged bands are useful internal observations but cannot be assumed to be validated loading controls merely because their intensities look similar.

The most informative difference is phosphorylation without PDGF, relative to sample A. The following are candidate interpretations of the supplied Western blot, not definitive clinical diagnoses or protein identifications:

A single broad phospho-antibody cannot reliably distinguish the closely sized MEK and ERK bands or determine whether any phosphorylation site is activating. Clinical assessment and genetic and functional confirmation remain necessary.

Use a total-protein stain or validated constitutive loading control, and measure total amounts of the candidate signaling proteins alongside their site-specific phosphorylated forms. This distinguishes increased phosphorylation fraction from increased protein abundance. Include a no-primary or secondary-only control and a phosphatase-treated aliquot to test phospho-dependent detection. Confirm candidate identities using validated target-specific phospho-antibodies, suitable positive controls and, where feasible, depletion or inhibition of the relevant target. Repeat the paired time course with biological replicates and non-saturated imaging. Matching culture state, stimulus dose and sampling time is essential because an ordinary difference in response kinetics could otherwise mimic constitutive activation.

An activating Ras lesion is a parsimonious candidate, because Ras lies upstream of the branch to Raf and the branch to phosphoinositide 3-kinase. Persistent GTP-bound Ras can therefore produce both basal patterns through a single change. A lesion restricted to MEK would not directly explain the simultaneous Akt signal. The blot does not uniquely locate the mutation: a constitutively active upstream receptor tyrosine kinase or altered regulation of Ras could also activate both branches. Test the Ras nucleotide state, sequence relevant genes, and determine which targeted perturbation suppresses both outputs.

mTOR has the supplied molecular mass of about $259\mathrm{kDa}$, so optimize the separation and transfer for a much larger protein. Use a suitably low-percentage or gradient SDS-PAGE gel and high-mass markers, and verify efficient transfer with a protocol appropriate for large proteins, such as optimized wet transfer. Probe with a validated phospho-mTOR reagent and measure total mTOR in parallel. The broad Ras-PST25 reagent cannot be assumed to recognize a useful site on mTOR merely because it recognizes other pathway proteins. Include a positive pathway control and a suitable inhibition or phosphatase control; a missing band on the existing blot could reflect poor separation or transfer rather than absent mTOR phosphorylation.

Analyze the corresponding region from a parallel preparative SDS-PAGE gel, digest the recovered proteins and identify peptides by liquid chromatography-mass spectrometry. The lane and gel region should match the $35\mathrm{kDa}$ signal, with an adjacent-background or control-sample region processed in parallel. Because several proteins can comigrate, validate the candidate against the actual phospho-band, for example by immunoprecipitating the candidate and testing Ras-PST25 reactivity, using a target-specific Western blot, or showing disappearance of the band after specific depletion. Phosphopeptide identification provides additional evidence; mass alone or detecting a common contaminant in the excised region is insufficient.

PDGFR is a receptor tyrosine kinase; its key ligand-induced autophosphorylation is on tyrosine residues. Ras-PST25 recognizes phosphorylated serine residues and threonine residues, so it is not the appropriate reagent to detect the characteristic activated PDGFR phosphotyrosines. Use a phosphotyrosine or validated phospho-PDGFR antibody, ideally alongside total PDGFR. The larger receptor may also require a different gel and transfer range, but changing the size range alone would not correct the epitope mismatch.

One candidate inward-facing PCR primer pair, written $5^{\prime }$ to $3^{\prime }$, isThe forward PCR primer binds the intronic flank immediately upstream of exon 5; the reverse PCR primer is the reverse complement of a downstream exon-5 segment. Their amplicon includes the repeat while both binding sites lie outside it. Using the displayed reference sequence gives an approximately $122$-base-pair product; an indel changes the intervening length and sequence. The primers have matched simple Wallace-rule estimates near $60{}^{\circ }\mathrm{C}$. These are candidates from the supplied sequence: confirm genomic specificity, absence of variable primer-binding sites, secondary structures and actual reaction conditions before use. Sequence from a unique flank toward the repeat and verify a single specific product.

Two desirable properties are similar primer melting temperatures, allowing one annealing condition to support both primers efficiently, and specific binding with little self-complementarity or mutual complementarity, especially at the $3^{\prime }$ ends, to reduce off-target products and primer dimers. Suitable length and a balanced GC content help achieve these goals. A long homopolymer, strong hairpin or repeated genomic binding site would compromise a candidate even if its calculated melting temperature looked acceptable.

The repetitive tract can cause DNA polymerase slippage during PCR amplification or the sequencing extension itself, generating stutter products. A heterozygous length variant creates overlapping Sanger sequencing traces downstream of the indel because the two templates lose register; this does not by itself indicate random sequencing failure. Tumor heterogeneity or contamination by normal tissue can add further mixed templates. Avoid creating or obscuring the mutation during amplification and avoid interpreting a mixed trace as one clean allele. Use a suitable high-fidelity DNA polymerase, independent amplifications and bidirectional reads, and resolve individual alleles by molecular cloning or an appropriate single-molecule/amplicon sequencing method if necessary. Check for non-specific products and allelic dropout caused by variation in a primer-binding site.

A practical design uses one common exon-4 forward PCR primer with an exon-specific reverse PCR primer for each transcript isoform. Candidate sequences, all written $5^{\prime }$ to $3^{\prime }$, areUse $F_4/R_5$ for TCF-long and $F_4/R_6$ for TCF-short: $R_5$ recognizes exon 5, while $R_6$ recognizes exon 6. The displayed mature reference sequences predict approximately $130$- and $67$-base-pair products, respectively. Check actual splice products because a transcript with unexpected exon combinations could defeat the assumed specificity. The simple melting-temperature estimates are approximately $62$, $60$ and $60{}^{\circ }\mathrm{C}$.

Prepare matched RNA, remove contaminating DNA, carry out reverse transcription and validate each RT-qPCR assay with known isoform standards, a single-product check, a no-template control and a no-reverse-transcriptase control. The primers span an intron in the genomic arrangement but do not themselves cross a splice junction, so the DNA control remains important. Calibrate amplification efficiency and fluorescence response before comparing molecule numbers between the two assays. A redesigned junction-specific assay is another option once additional suitable flanking sequence is available.

Use RNA sequencing and quantify reads spanning the exon-4/exon-5 and exon-4/exon-6 splice junctions, with appropriate normalization for informative read opportunities. These distinguish production of the long- and short-associated transcript isoforms rather than merely measuring total TCF transcription factor transcripts. Adequate junction coverage and biological replication are required; long-read RNA sequencing can independently check whether the assumed complete isoforms are present. This avoids relying on a comparison of raw Ct values from two different PCR primer pairs.

Using the stated curve assignments, read approximately $C_{t,S}=24$ and $C_{t,L}=26$ for Caco-2, and $C_{t,S}=24$ and $C_{t,L}=30$ for differentiated Caco-2. If both assays double product per cycle and have comparable threshold calibration,Therefore TCF-short:TCF-long is approximately $4:1$ in Caco-2 and $64:1$ after differentiation. The short:long ratio rises about sixteenfold; under the supplied legend, this pilot result does not support preferential expression of TCF-long after differentiation. These are approximate graph-based estimates, particularly because fractional-cycle readings can noticeably change a large ratio. Cross-assay molecule ratios require validated efficiencies and calibration standards; equal-looking plateaus do not establish either assumption.

A housekeeping Ct is unnecessary for the within-sample short:long ratio, because a common reference cancels. With matched doubling efficiencies,However, a validated reference such as TATA-binding protein transcript is needed when comparing the abundance of either isoform separately between samples while correcting for input, RNA recovery and reverse transcription. Reference stability must be tested under the differentiation conditions. Neither reference normalization nor cancellation removes the need to validate the two isoform assays' efficiencies and response calibration.

The ascending-colon tumors carry the exon-5 frameshift mutation in $3/4$ sampled patients, transverse tumors in $1/2$, and descending and sigmoid tumors in $0/2$ each. Grouping these gives $4/6$ proximal tumors versus $0/4$ distal tumors with the repeat alteration, suggesting proximal enrichment of this molecular subtype. The matched samples show a one-allele alteration in the adjacent tissue of patients 1 and 7, whereas patients 5 and 9 have tumor-associated alterations without a detected alteration in their matched normal sample.

This is a small case series, and all ten patients already have tumors. It cannot determine whether a region has a higher absolute risk of transformation, nor establish defective DNA mismatch repair from one altered repeat alone. Larger location-matched series, population denominators, testing of additional microsatellites and direct assessment of DNA mismatch repair components are needed to support those stronger claims.

The lower region can contain both the genuine TCF-short product and a truncated product derived from the exon-5-containing TCF-long transcript. A repeat frameshift mutation creates an early stop codon, producing a long-derived product close in size to TCF-short. The N-terminal antibody recognizes their shared retained region. The two nearby bands need not represent two copies of the normal short splice product. In patient 1's healthy sample, one mutated allele permits a truncated product alongside intact long and short products; in the tumor, mutation of both alleles explains loss of the intact long band while short-sized products remain. Test the assignment with an exon-5/C-terminal-specific reagent or peptide identification; phosphorylation or other modifications could also create doublets, so mobility alone is not definitive.

Prepare nuclear extract from the specified pancreatic cell line, retaining DNA-binding activity and protecting against degradation. Make and label a double-stranded DNA probe containing the two candidate binding sites and their flanks. Incubate equal probe amounts with extract under suitable binding conditions, including non-specific competitor DNA. Prepare the extract-only binding reaction and separate reactions containing anti-TCF transcription factor or anti-HNF1β antibody; keep other conditions and input amounts matched. Resolve the reactions by non-denaturing polyacrylamide gel electrophoresis and detect the labelled probe. Binding changes probe mobility; addition of an appropriate antibody can produce a supershift. Include probe integrity and a probe-only reference, and avoid denaturing reagents that destroy the complexes being measured.

It is the free labelled DNA probe, not bound in the slower-moving protein–DNA complexes. Its smaller effective hydrodynamic size allows faster migration. Excess unbound probe commonly gives a strong lower band; a probe-only lane would verify this assignment and distinguish it from a labelled degradation product.

A strong specificity control is competition with a large excess of unlabelled cognate promoter DNA. It should reduce the shifted labelled complexes, whereas an unrelated or binding-site-mutant competitor should compete much less effectively. This tests sequence-dependent association rather than non-specific probe retention. A probe-only lane identifies the free probe, and an irrelevant isotype-matched antibody controls whether any added antibody produces aggregation or altered mobility. These controls address different uncertainties and should not be treated as interchangeable.